Oppenheimer Holdings reaffirmed its 'outperform' rating, and TD Cowen reaffirmed a 'buy' rating for Praxis Precision Medicines.
1 report, 1 independent
Updated Jun 12
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Oppenheimer Holdings reaffirmed its 'outperform' rating, and TD Cowen reaffirmed a 'buy' rating for Praxis Precision Medicines.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Oppenheimer Holdings
investment bank and investment firm
-
TD Cowen
American investment bank
Related events
- TD Cowen upgraded Crescent Biopharma shares to 'strong-buy', while Wedbush reiterated 'outperform', and a CEO sold shares under a 10b5-1 plan.
- TD Cowen issued a buy rating and price target for Evolv Technologies Holdings, Inc.
- Rating firms Raymond James Financial and TD Cowen provided reaffirmed buy ratings and price targets for a company listed on Nasdaq.
- Raymond James Financial and TD Cowen issued rating updates for GDS, alongside an insider transaction disclosure filed with the SEC.
- TD Cowen maintained a Buy rating on Forgent on September 15, 2026.